...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and diagnostic laboratory immunology >Treatment with Neurokinin-1 Receptor Antagonist Reduces Severity of Inflammatory Bowel Disease Induced by Cryptosporidium parvum
【24h】

Treatment with Neurokinin-1 Receptor Antagonist Reduces Severity of Inflammatory Bowel Disease Induced by Cryptosporidium parvum

机译：Neurokinin-1受体拮抗剂治疗可降低小隐隐孢子虫引起的炎性肠病的严重性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Inflammatory bowel disease (IBD) is a chronic, debilitating disorder of uncertain and perhaps multiple etiologies. It is believed to be due in part to disregulation of the immune system. Neuroimmune interactions may be involved in induction or maintenance of IBD. In the present study, we examined the potential role of a neurotransmitter, substance P, in a mouse model of IBD. We found that binding sites for substance P, and more specifically, neurokinin-1 receptors, were upregulated in intestinal tissue of mice with IBD-like syndrome. Dosing of mice with LY303870, a neurokinin-1 receptor antagonist, reduced the severity of IBD, and treatment of mice with preexisting IBD allowed partial healing of lesions. We hypothesize that blocking the binding of substance P to the neurokinin-1 receptor interrupts the inflammatory cascade that triggers and maintains intestinal lesions of IBD.
机译：炎症性肠病（IBD）是一种慢性的，令人衰弱的疾病，病因可能不确定，可能有多种。据信部分原因是免疫系统失调。神经免疫相互作用可能与IBD的诱导或维持有关。在本研究中，我们检查了IBD小鼠模型中神经递质P的潜在作用。我们发现P物质，更具体地说，神经激肽1受体的结合位点在IBD样综合征小鼠的肠组织中被上调。用神经激肽-1受体拮抗剂LY303870给药，可减轻IBD的严重程度，并用已存在的IBD治疗小鼠可部分治愈病变。我们假设阻止P物质与神经激肽1受体的结合会中断触发和维持IBD肠道病变的炎症级联反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号